AI‑Driven Startup Aims to Keep Human Skin Alive for Skincare Research
What changed
After years of development, Michael Polansky's AI‑focused startup is now publicly announced.
The core of the venture is a system that maintains living human skin tissue ex vivo for several weeks, allowing AI models to evaluate new skincare compounds directly on living tissue.
“Michael Polansky — better known publicly as Lady Gaga's partner and a former top deputy to Sean Parker — has quietly spent years building an AI‑driven startup that keeps living human skin tissue alive for weeks outside the body to discover new skincare compounds, and is only now going public about it.”
Why it matters
Speeding discovery: Traditional skincare testing relies on in‑vitro assays or animal models, which can miss nuances of living human skin. Extending the viability of skin samples could let AI evaluate compounds in a more realistic context.
AI integration: By pairing viable tissue with AI, the company hopes to sift through large chemical libraries faster than manual lab work.
Who is affected
Skincare brands: Companies looking for novel actives may gain a new research pathway.
Consumers: If the approach shortens development cycles, new products could reach shelves more quickly.
Investors: The blend of biotech and AI may attract capital interested in next‑generation beauty tech.
What to watch next
Regulatory clearance: Ex vivo human tissue use typically requires ethical oversight; observers will monitor any approvals the startup seeks.
Partnership announcements: Early collaborations with cosmetics firms could signal market traction.
Technical validation: Independent labs may attempt to replicate the tissue‑keeping method to confirm its reproducibility.
Source: TechCrunch, 22 Aug 2026.